Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 2/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5572886 | 0.83 | — | — | |
| SCHEMBL5725177 | 0.79 | P2RY6 (0.48) | P2RY6MIFCA1CA2HSD17B10 | |
| SCHEMBL2217784 | 0.79 | MIF (0.67) | P2RY6MIFCA1CA2FFAR1 | |
| SCHEMBL23051721 | 0.78 | P2RY6 (0.47) | P2RY6MIFCA1CA2FFAR1 | |
| SCHEMBL14996343 | 0.78 | APP (0.48) | P2RY6MIFCA1CA2HSD17B10 | |
| SCHEMBL17225183 | 0.78 | P2RY6 (0.47) | P2RY6MIFCA1CA2FFAR1 | |
| SCHEMBL19057508 | 0.78 | P2RY6 (0.47) | P2RY6MIFCA1CA2HSD17B10 | |
| SCHEMBL14996360 | 0.78 | APP (0.48) | P2RY6MIFCA1CA2HSD17B10 | |
| SCHEMBL1649302 | 0.78 | HDAC8 (0.55) | FFAR1GRM5HDAC8PIK3CAMTOR | |
| SCHEMBL19174378 | 0.75 | P2RY6 (0.48) | P2RY6MIFCA1CA2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110282031-A1 | A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES | WILSON CONSTANCE N (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282031-A1 | A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES | ADORA1, ADORA3, ADORA2A | P2RY6 41/4885MIF 3477/4885CA1 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.